Latest News and Press Releases
Want to stay updated on the latest news?
- 
                            
Court approves $37.5M cash settlement with Silvergate Capital Corporation in investor securities class action in the wake of FTX cryptocurrency fraud.
 - 
                            
Antitrust class action accuses some of the nation’s most prestigious colleges of conspiring to inflate tuition through the early decision process.
 - 
                            
DENVER, July 21, 2025 (GLOBE NEWSWIRE) -- Cohen Milstein Sellers & Toll PLLC announces that the United District Court for the District of Colorado has approved the following announcement of a...
 - 
                            
Following the Bayer-Monsanto merger, litigation has resulted in a valuable settlement that, pending final approval, affirms the rights of ADR investors to
 - 
                            
Cohen Milstein encourages GoHealth, Inc. (GOCO) investors to contact firm about an investigation into GoHesecurities fraud and other securities violations.
 - 
                            
Zenas BioPharma investors are encouraged to call Cohen Milstein's Molly Bowen, Esq. about becoming a lead plaintiff in the ZBIO stock drop class action.
 - 
                            
Zenas BioPharma investors have until June 16 to sign up to become a Lead Plaintiff in this securities class action. For more information, call Molly Bowen.
 - 
                            
Cohen Milstein continues lead plaintiff Search for Zenas BioPharma (ZBIO) securities fraud class action. Contact Molly Bowen, Esq. at 1 (202) 408-4600.
 - 
                            Cohen Milstein Reminds Zenas BioPharma (ZBIO) Investors of Opportunity to Lead Securities Fraud Suit
Cohen Milstein reminds Zenas BioPharma (ZBIO) investors of an opportunity to lead a securities fraud class action. Lead plaintiff deadline - June 16, 2025.
 - 
                            
Cohen Milstein seeks Zenas BioPharma (ZBIO) investors to join and/or lead class action to hold Zenas BioPharma accountable for IPO-related fraud.